title: [AT(1) blocker for post-infarct therapy. VALIANT Study].
authors.affiliation: Zentrum Innere Medizin, Kardiologie und Pneumologie, Georg-August-Universität, Robert-Koch-Strasse 40, 37075 Göttingen. cschulz@med.uni-goettingen.de
authors.forename: G
authors.initials: G
authors.lastname: Hasenfuss
mesh_terms: D000328:Adult; D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D002216:Captopril / Q000009:adverse effects / Q000627:therapeutic use*; D002423:Cause of Death; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D016019:Survival Analysis; D013577:Syndrome; D013777:Tetrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014633:Valine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000068756:Valsartan; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy* / Q000401:mortality
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D013777:Tetrazoles; D000068756:Valsartan; D002216:Captopril; D014633:Valine